GlassScriptPhysician profile
Sandra L Urtishak
NPI 1932358769
$2,480.50
in general payments reported to CMS, 2019-2025
33 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $68.85 · 2022: $45.00 · 2023: $273 · 2024: $864 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $317.73 | 2023-2025 | |
| Pfizer INC. | $231.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $199.72 | 2020-2025 | Imfinzi, Enhertu, Tagrisso |
| Alexion Pharmaceuticals, INC. | $172.21 | 2019-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $160.48 | 2019-2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $145.58 | 2019-2025 | Lynparza, Keytruda |
| Eisai INC. | $114.42 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.95 | 2023-2025 | Ninlaro, Iclusig |
| Celgene Corporation | $73.19 | 2019-2024 | Reblozyl, Opdualag |
| Sobi, INC | $70.02 | 2024-2025 | |
| Tempus Ai, INC | $69.78 | 2024-2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $67.25 | 2024-2025 | Onivyde |
| Incyte Corporation | $64.04 | 2024-2025 | Monjuvi, Pemazyre, Zynyz |
| Amgen INC. | $60.13 | 2019-2023 | Xgeva, Nplate |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.20 | 2019-2020 | |
| Exelixis INC. | $49.73 | 2023-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $48.06 | 2022-2023 | Imbruvica |
| Daiichi Sankyo INC. | $44.44 | 2024-2025 | Enhertu |
| Array Biopharma INC | $40.57 | 2019-2024 | Mektovi, Braftovi |
| Janssen Biotech, INC. | $37.12 | 2020-2025 | Rybrevant |
| Immunocore Limited | $29.87 | 2025 | Kimmtrak |
| Kite Pharma, INC. | $26.86 | 2024 | Yescarta |
| Gilead Sciences, INC. | $26.45 | 2022 | |
| Aveo Pharmaceuticals, INC. | $24.38 | 2025 | |
| Servier Pharmaceuticals LLC | $22.94 | 2024 | |
| G1 Therapeutics, INC. | $22.56 | 2023 | Cosela |
| Genentech USA, INC. | $21.84 | 2023 | Polivy, Lunsumio, Columvi |
| Clovis Oncology, INC. | $19.48 | 2019 | |
| Genmab U.S., INC. | $19.27 | 2023 | Tivdak |
| Tesaro, INC. | $19.08 | 2019 | |
| Abbvie INC. | $13.14 | 2020 | |
| Taiho Oncology, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Urtishak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.